Skip to main content
Citius Pharmaceuticals, Inc. logo

Citius Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · CTXR ISIN · US17322U2078 LEI · 5493005C10W36P4KQP40 US Manufacturing
Open in API
Filings indexed 623 across all filing types
Latest filing 2015-10-14 Board/Management Inform…
Country US United States of America
Listing US CTXR

About Citius Pharmaceuticals, Inc.

https://www.citiuspharma.com/

Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company that develops and commercializes critical care products. The company's diversified pipeline focuses on anti-infectives in adjunct cancer care, stem cell therapies, and prescription products. Its portfolio includes LYMPHIR™, an FDA-approved therapy for adult patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Key product candidates in development include Mino-Lok®, an antibiotic lock solution intended to treat patients with catheter-related bloodstream infections, and Halo-Lido, a topical formulation for the treatment of hemorrhoids. Additionally, the company is advancing a stem cell therapy platform for conditions such as acute respiratory distress syndrome (ARDS).

Recent filings

Filing Released Lang Actions
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated October 14, 2015, reporting the appointment of a new board member, Suren Dutia, including details about his background and stock option grants. The key content is about changes in the company's board of directors and related compensatory arrangements. There is no financial report or earnings data presented. The document fits the category of announcements related to changes in board or senior management. Therefore, the appropriate classification is Board/Management Information (MANG). The document length and content confirm it is not a brief announcement or a report publication notice, but a full disclosure of management changes.
2015-10-14 English
Regulatory Filings 2015
Regulatory Filings
2015-10-09 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated October 1, 2015. It reports the appointment of a new board member, Mr. Myron Holubiak, including details about his background and the stock options granted to him. The key content is about changes in the company's board of directors and related compensatory arrangements. There are no financial statements or earnings data, nor is this a report or announcement of a report publication. The document fits the category of Board/Management Information (MANG) as it announces changes in the company's board of directors and senior management.
2015-10-06 English
FORM S-1
Capital/Financing Update Classification · 95% confidence The document is a Form S-1 Registration Statement filed with the SEC, dated September 11, 2015, for Citius Pharmaceuticals, Inc. It is a registration statement under the Securities Act of 1933, used for registering securities for public offering. The text includes detailed information about the securities being registered, the company background, the offering, and related legal and financial disclosures. This type of filing is related to capital raising and financing activities, specifically the registration of shares for sale to the public. It is not an annual report, earnings release, or other financial report, but a capital markets filing to register securities for sale. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is the actual registration statement, not just an announcement or certification, so it is not RPA or RNS. Confidence is high given the clear identification of the form and content.
2015-09-11 English
FORM 10-Q
Interim / Quarterly Report 9M 2015
2015-08-12 English
FORM 10-Q
Interim / Quarterly Report Q2 2015
2015-05-13 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.